SEREX, Proteomex, AMIDA, and beyond: Serological screening technologies for target identification

scientific article published on 07 February 2008

SEREX, Proteomex, AMIDA, and beyond: Serological screening technologies for target identification is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1002/PRCA.200780064
P698PubMed publication ID21136839

P50authorJens RauchQ37837239
Olivier GiresQ37837254
P2860cites workEpCAM: A New Therapeutic Target for an Old Cancer AntigenQ28204907
Immunohistochemical studies in the identification of lymph node micrometastases in patients with squamous cell carcinoma of the head and neckQ35753645
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomasQ36362111
Autoantibody biomarkers in the detection of cancerQ36490701
CD4 T cell-dependent autoimmunity against a melanocyte neoantigen induces spontaneous vitiligo and depends upon Fas-Fas ligand interactions.Q50744819
P433issue3
P304page(s)355-371
P577publication date2008-02-07
P1433published inProteomics - Clinical ApplicationsQ15754475
P1476titleSEREX, Proteomex, AMIDA, and beyond: Serological screening technologies for target identification
P478volume2